CD30/CD30L and CD40/CD40L are molecules from the tumor necrosis factor (TNF) superfamily. They have a major effect on communications between the B and T cells, which leads to control of maturation, proliferation, and apoptosis of those cells. The aim of this study was to compare the levels of a soluble form of CD30 (sCD30) and a soluble ligand CD40 (sCD40L) in patients with systemic lupus erythematosus (SLE) (n=65) and healthy controls (sCD30 n=20, sCD40L n=10) with other parameters of SLE activity. Patients were divided into subgroups according to presence or absence of lupus nephritis (LN; 33 with LN, 32 without LN). The serum levels of selected parameters were assessed also in the subgroups with low active disease characterized by European Lupus Activity Measure (ECLAM) at most 3(n=29) and active disease with ECLAM more than 3 (n=36). The serum levels of sCD30 were 66.0+/-40.2 UI/ml in the whole group. The mean serum levels were 60.0+/-45.2 UI/ml in the subgroups with LN, 67.1+/-38.9 UI/ml in the subgroup without LN, 80.2+/-51.9 UI/ml in the subgroup with active disease, 55.4+/-24.1 UI/ml in the subgroup with low active disease, and finally, 40.1+/-19.2 U/ml in the controls. Significant differences were found between the SLE patients and controls (p=0.0001) and between the active and nonactive groups (p=0.002). A correlation was found between levels of CD30 and ECLAM (r=0.25, p

3 Department of Internal Medicine Faculty of Medicine and Faculty Hospital University of Olomouc 1 P Pavlova 6 Olomouc 775 20 Czech Republic

Clin Rheumatol. 2007 May;26(5):852 PubMed

Clin Rheumatol. 2007 May;26(5):852. doi: 10.1007/s10067-007-0571-8. PubMed

Zobrazit více v PubMed

Clin Rheumatol. 2001;20(5):337-44 PubMed

Blood. 2000 Dec 15;96(13):4307-12 PubMed

J Clin Invest. 2004 Sep;114(5):679-88 PubMed

AMA Arch Derm Syphilol. 1953 Aug;68(2):119-28 PubMed

Acta Med Okayama. 2003 Dec;57(6):267-77 PubMed

Clin Exp Rheumatol. 1992 Sep-Oct;10(5):549-54 PubMed

Mol Aspects Med. 1996 Oct;17(5):455-509 PubMed

Arthritis Rheum. 1992 Jun;35(6):630-40 PubMed

J Clin Invest. 1999 Oct;104(7):947-55 PubMed

J Clin Invest. 1996 Aug 1;98(3):826-37 PubMed

Clin Rheumatol. 2006 Jul;25(4):532-6 PubMed

J Rheumatol. 2001 Jan;28(1):95-101 PubMed

Adv Immunol. 1985;37:151-216 PubMed

Blood. 1995 Jan 1;85(1):1-14 PubMed

Ther Apher Dial. 2005 Feb;9(1):64-8 PubMed

Arthritis Res. 2002;4 Suppl 3:S279-93 PubMed

J Clin Invest. 2006 Mar;116(3):724-34 PubMed

Arthritis Rheum. 1982 Nov;25(11):1271-7 PubMed

Rheumatology (Oxford). 2003 Jan;42(1):117-22 PubMed

J Autoimmun. 2006 May;26(3):165-71 PubMed

Clin Exp Rheumatol. 1995 May-Jun;13(3):339-43 PubMed

Ann N Y Acad Sci. 2005 Jun;1051:433-41 PubMed

Lupus. 1999;8(8):632-7 PubMed

Serum protein pattern associated with organ damage and lupus nephritis in systemic lupus erythematosus revealed by PEA immunoassay